Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION775 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ION775: Cohot A | EXPERIMENTAL | Participants will be randomized to receive ION775 by subcutaneous (SC) injection. |
| ION775: Cohot B | EXPERIMENTAL | Participants will be randomized to receive ION775 by SC injection. |
| ION775: Cohot C | EXPERIMENTAL | Participants will be randomized to receive ION775 by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION775 | DRUG | ION775 will be administered by SC injection. |
Key Inclusion Criteria: 1. Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg/dL) \[3.95 millimoles per liter (mmol/L)\] or with sHTG (fasting TG ≥ 500 mg/dL \[5.65 mmol/L\]). 2. Participants should be on standard of care lipid-lowering medicatio...
ION775 is an investigational small molecule being developed for the treatment of hypertriglyceridemia, including severe hypertriglyceridemia. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
ION775 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting a Phase 2 clinical trial to evaluate the drug's safety, tolerability, and efficacy in patients with hypertriglyceridemia.
ION775 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 study is actively recruiting participants to assess its safety, tolerability, and efficacy in patients with hypertriglyceridemia.
ION775 is being studied in a Phase 2 clinical trial with the identifier NCT07604974. This randomized, controlled study is recruiting approximately 72 participants with hypertriglyceridemia or severe hypertriglyceridemia at sites in the United States and Canada. The trial is currently active and recruiting.
ION775 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of hypertriglyceridemia. The ongoing clinical trial is designed to assess its safety, tolerability, and efficacy, but regulatory approval has not been granted.